DELFI Diagnostics
Saving Lives Through Early Cancer Detection
- Headquarters
- Baltimore, Maryland
- Employees
- 51–200
- Founded
- 2019
- Business Model
- B2B
- Website
- delfiagnostics.com
- Total Funding
- $364.8M
- Last Round
- $34.3M Venture RoundDec 2025
About
DELFI Diagnostics pioneers fragmentomics technology, analyzing cell-free DNA fragments from blood samples using advanced machine learning and next-generation sequencing for early cancer detection and monitoring. Their DELFI platform scans millions of data points to identify cancer signals with high sensitivity, supporting providers and pharma in treatment decisions. Developed by experts in genomics, AI, and cancer biology.
Tech Stack
AI/ML
Machine Learning
Other
Next-Generation Sequencing
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free Account